Abzena Group
 
    
                    Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an Australian, New Zealand and UK  based service group, offering full and integrated drug development  consultancy to small – medium sized Biotech companies from inception  through to end of phase II clinical trial programs. CNS offers a unique  service that brings together BioDesk; an intelligent product development  and regulatory planning service, with our highly experienced regional  clinical operations and data management teams. 
 
 BioDesk is a team of in-house scientists and commercial drug development  experts, who work closely with our clients from the earliest of  planning stages. Together they create and manage Drug Development Plans,  including all stages of pre-clinical/CMC programs that embrace global  regulatory strategies whilst leveraging our unique regional advantage.
 
 Australia and New Zealand have an outstanding product development  timeline advantage due to our access to a pragmatic regulatory  environment that makes it possible to add value to the global regulatory  dossier and enter the clinic quickly, without the need for prior  approval from another regulatory agency. Our clients have often  established initial proof-of-concept quickly, and have enjoyed a  time(cost) saving when compared to the more resource-intensive strategy  of applying for an IND or CTA. 
 
 CNS has worked with clients whose cumulative acquisition price exceeds  US$16.5billion; many of these clients initially fast-tracked their  programs by running their phase 1 & 2 studies in Australia and New  Zealand.
 
    
                    Domainex Ltd
Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates.


 
    
                    